2006
Antithrombin reduces monocyte and neutrophil CD11b up regulation in addition to blocking platelet activation during extracorporeal circulation
Rinder CS, Rinder HM, Smith MJ, Fitch JC, Tracey JB, Chandler WL, Rollins SA, Smith BR. Antithrombin reduces monocyte and neutrophil CD11b up regulation in addition to blocking platelet activation during extracorporeal circulation. Transfusion 2006, 46: 1130-1137. PMID: 16836559, DOI: 10.1111/j.1537-2995.2006.00861.x.Peer-Reviewed Original ResearchConceptsNeutrophil elastase releaseAnti-inflammatory activityAntithrombin IIICardiopulmonary bypassElastase releasePlatelet activationWhite blood cell activationDirect anti-inflammatory activitySystemic inflammatory reactionAbsence of endotheliumEndothelial effectsCardiac surgeryBlood cell activationAnticoagulant effectExtracorporeal circulationInflammatory reactionThrombin generationHigh doseClinical relevanceCell activationFibrin generationComplement activationThrombin activityStudy designCD11b
1990
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. Journal Of Clinical Oncology 1990, 8: 648-56. PMID: 2313334, DOI: 10.1200/jco.1990.8.4.648.Peer-Reviewed Original ResearchConceptsAutologous bone marrow transplantationMaximum-tolerated doseBone marrow transplantationRelapsed lymphomaComplete responseMarrow transplantationDose levelsVP-16Refractory Hodgkin's diseaseTreatment-related mortalityDose-finding studyAssessable patientsAcceptable toxicityConditioning regimenInterstitial pneumonitisHodgkin's diseaseResidual diseaseHodgkin's lymphomaPatient populationDisease progressionHigh dosePatientsLymphomaDiseaseCBV